Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
NIH BRAIN Initiative Director John Ngai and Acting NINDS Director Amy Bany Adams jointly announced the formal publication of the BRAIN Initiative's 10-year Neuroscience Research Roadmap on 15 May 2026, with a Director's Message and a paper in Neuron. The roadmap, finalised in August 2025, organises the next decade of US federally-funded neuroscience around four Innovation Domains: BRAIN Knowledgebase, Precision Molecular Circuit Therapies, Accelerating Human Neuroscience, and BRAIN NeuroAI.
Medtronic announced on 20 May 2026 its intent to acquire SPR Therapeutics, the maker of the Sprint percutaneous peripheral nerve stimulation system, for approximately $650 million in upfront cash. The deal is the second top-three neuromodulation acquisition of a PNS specialist in seven months, after Boston Scientific completed its $533 million purchase of Nalu Medical in January 2026.
Governor Phil Scott signed H.814 into law on 18 May 2026, making Vermont the fifth US state with neural data privacy legislation on the books after Colorado, California, Montana, and Connecticut. The enacted text is the 6-page version of a bill that originally cleared the House at 32 pages; the consent requirement and private right of action did not survive the Senate amendment process. Effective 1 July 2026.
Mobia Medical, the company behind the only FDA-approved implanted vagus nerve stimulator for chronic stroke recovery, priced its $150 million IPO at $15 on 7 May 2026 and closed week one at $11.75. The print resets implied exit math for the pre-IPO bioelectronic-medicine cohort preparing 2026-27 listings.
BlueWind Medical closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale US commercialisation of Revi, the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence. The round follows three-year OASIS pivotal trial data and Medtronic's September 2025 FDA approval of its competing Altaviva tibial system.
Imperial College London spinout MintNeuro signed a multi-year commercial supply agreement on 6 May 2026 to provide its miniaturised sensing and stimulation integrated circuits to Motif Neurotech's DOT depression implant across pre-clinical, early clinical, and pivotal trial phases. The deal lands two weeks after Motif's FDA Investigational Device Exemption clearance.
NeuroPace reported Q1 2026 RNS System revenue of $21.7 million (up 19.5% year-on-year), raised full-year guidance to $99-101 million, and detailed 18-month NAUTILUS trial data showing a 77% median reduction in generalised tonic-clonic seizures. FDA paused the 180-day clock on the expanded-indication review; midyear determination still anticipated.
Illinois Institute of Technology and Rush University Medical Center completed the third implantation of the Intracortical Visual Prosthesis on 7 May 2026, a 34-stimulator, 544-electrode wireless system bypassing the eye and optic nerve to deliver artificial sight directly to the visual cortex.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.